T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia.

T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia.
复制标题

DOI:
10.1136/jitc-2021-002509
复制
发表时间:
2021-05
影响因子:
10.9
通讯作者:
Cheung NV
Cheung NV
中科院分区:
医学2区
文献类型:
--
作者:
Hoseini SS;Vadlamudi M;Espinosa-Cotton M;Tran H;Feng Y;Guo HF;Xu H;Cheung I;Cheung NV

文献摘要

参考文献

被引文献

相似文献

急性髓系白血病(AML)是最具挑战性的血液系统恶性肿瘤之一。尽管在治疗方面取得了进展,但大多数患者死于这种肿瘤。鉴于其在大多数AML细胞上的表达,CD 33是经证实的治疗靶点。几乎所有抗CD 33抗体都靶向CD 33细胞外结构域的膜远端免疫球蛋白V(IgV)结构域。在这份手稿中,我们提出了三个双特异性抗体(BsAb)的CD 33 IgV和近膜免疫球蛋白C(IgC)结构域的数据。我们使用体外结合和细胞毒性测定来显示这些BsAb对AML细胞系的作用。我们还使用免疫缺陷小鼠白血病细胞系和患者来源的异种移植物,以显示这些BsAb在体内的效果。在体外,IgV靶向BsAb具有更高的结合AML细胞系使用流式细胞术,并提供更有效的细胞毒性T细胞依赖性细胞毒性试验;重要的是,IgC结构域靶向优于IgV结构域靶向BsAb在髓和髓外白血病动物模型。这些数据支持该BsAb用于首次人体I期临床试验的进一步临床开发。
Acute myeloid leukemia (AML) remains one of the most challenging hematological malignancies. Despite progress in therapeutics, majority of patients succumb to this neoplasm. CD33 is a proven therapeutic target, given its expression on most AML cells. Almost all anti-CD33 antibodies target the membrane distal immunoglobulin V (IgV) domain of the CD33 extracellular domain. In this manuscript, we present data on three bispecific antibodies (BsAbs) against the CD33 IgV and membrane proximal immunoglobulin C (IgC) domains. We use in vitro binding and cytotoxicity assays to show the effect of these BsAbs on AML cell lines. We also use immunodeficient mice-bearing leukemias from cell lines and patient-derived xenografts to show the effect of these BsAbs in vivo. In vitro, the IgV-targeting BsAb had higher binding to AML cell lines using flow cytometry and delivered more potent cytotoxicity in T-cell-dependent cytotoxicity assays; importantly, the IgC domain-targeting outperformed the IgV domain-targeting BsAb in medullary and extramedullary leukemia animal models. These data support further clinical development of this BsAb for first-in-human phase I clinical trial.
DOI: 10.1182/bloodadvances.2019001188
发表时间: 2020-03-10
期刊: BLOOD ADVANCES
影响因子: 7.5
作者:
Nair-Gupta, Priyanka;Diem, Michael;Gaudet, Francois
通讯作者: Gaudet, Francois
DOI: 10.1200/jco.2016.71.2513
发表时间: 2017-08-10
影响因子: 45.3
作者:
Lamba, Jatinder K.;Chauhan, Lata;Meshinchi, Soheil
通讯作者: Meshinchi, Soheil
DOI: 10.1182/bloodadvances.2017014373
发表时间: 2018-06-12
期刊: BLOOD ADVANCES
影响因子: 7.5
作者:
Hoseini, Sayed Shahabuddin;Guo, Hongfen;Cheung, Nai-Kong V.
通讯作者: Cheung, Nai-Kong V.
DOI: 10.4081/pr.2020.8486
发表时间: 2020-01-01
期刊: PEDIATRIC REPORTS
影响因子: 1.1
作者:
Hao, Tran Kiem;Ha, Chau Van;Hiep, Pham Nhu
通讯作者: Hiep, Pham Nhu
DOI: 10.1158/2326-6066.cir-14-0230-t
发表时间: 2015-03-01
影响因子: 10.1
作者:
Xu, Hong;Cheng, Ming;Cheung, Nai-Kong V.
通讯作者: Cheung, Nai-Kong V.